The sialic acid content of fibrinogen decreases during pregnancy and increases in response to fibrate therapy.
Maghzal
Ghassan J
GJ
Molecular Pathology Laboratory Canterbury Health, Laboratories, P.O. Box 151 Christchurch, New Zealand. ghassan.maghzal@chmeds.ac.nz
Brennan
Stephen O
SO
George
Peter M
PM
D001629:Bezafibrate / Q000494:pharmacology*; D016022:Case-Control Studies; D005260:Female; D005340:Fibrinogen / Q000737:chemistry* / Q000187:drug effects*; D015248:Gemfibrozil / Q000494:pharmacology*; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000188:drug therapy; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D019158:N-Acetylneuraminic Acid / Q000032:analysis*; D011247:Pregnancy / Q000097:blood*; D021122:Protein Subunits; D021241:Spectrometry, Mass, Electrospray Ionization; D013918:Thrombin Time
C115499:BBeta fibrinogen; D000960:Hypolipidemic Agents; D021122:Protein Subunits; C464794:fibrinogen Aalpha; D005340:Fibrinogen; D019158:N-Acetylneuraminic Acid; D015248:Gemfibrozil; D001629:Bezafibrate